Invex Therapeutics Ltd

Invex Therapeutics Ltd is an Australia-based biopharmaceutical company. The Company is focused on the repurposing of an already-approved drug, Exenatide, for the efficacious treatment of neurological conditions derived from or involving raised intracranial pressure (ICP). In addition, the Company has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. The principal activity of the Company is the development of Exenatide, including generating new pre-clinical data in Alzheimer’s Disease (AD) under a collaboration with Tessara Therapeutics. The Company has trademarked its repurposed Exenatide as Presendin. The Company is focused on managing the close out of the Phase III Idiopathic Intracranial Hypertension (IIH) EVOLVE clinical trial and explore new potential applications for Exenatide in TBI and other neurological disorders with raised ICP, consistent with its patents.